HealthQuill cardiovascular diseases
Novo Nordisk’s medicine Wegovy, at a higher dose, resulted in an average weight loss of 21% during trials in people with obesity compared to a dummy drug, the company stated.
Drugs Health Pharma

Wegovy’s weight-loss efficacy improves with higher dosage

HQ Team June 21, 2025: Novo Nordisk’s medicine Wegovy, at a higher dose, resulted in an average weight loss of 21% during trials.

Read More
Eli Lilly and Company will acquire gene-editing startup Verve Therapeutics, Inc. for up to $1.3 billion to pocket an early-stage experimental therapy and to develop once-in-a-lifetime treatments for cardiovascular diseases.
Drugs Health Pharma

Eli Lilly to buy Verve for $1.3 billion, expands heart therapy segment

HQ Team June 19, 2025: Eli Lilly and Company will acquire gene-editing startup Verve Therapeutics, Inc. for up to $1.3 billion to pocket an.

Read More
Mental disorders have risen 70% across three decades, starting in 1990, in the Association of Southeast Asian Nations (ASEAN), affecting 80 million people in the region, according to a study.
Drugs Health Research

Mental disorders in ASEAN rise 70% in three decades: IHME, NUS study

HQ Team June 5, 2025: Mental disorders have risen 70% across three decades, starting in 1990, in the Association of Southeast Asian Nations.

Read More
Pfizer Inc. stopped its trial of danuglipron for treating chronic weight management after an asymptomatic patient developed a drug-induced liver injury that was resolved after discontinuation of the oral drug.
Uncategorized

Pfizer stops development of an investigational drug to treat obesity

HQ Team April 15, 2025: Pfizer Inc. stopped its trial of danuglipron for treating chronic weight management after an asymptomatic patient developed a.

Read More
The World Health Organization has issued new guidelines to help reform and strengthen mental health policies and systems at a time when up to 90% of the people in some nations with severe mental health conditions receive no care at all.
Health Medical Pharma

WHO unveils new guidelines to tackle mental health systems, policies

HQ Team March 26, 2025: The World Health Organization has issued new guidelines to help reform and strengthen mental health policies and systems.

Read More
The US Food and Drug Administration has greenlighted Pfizer Inc.’s respiratory syncytial virus vaccine (RSV) Abrysvo for treating lower respiratory tract disease in people 18-59 years.
Drugs Health Pharma

US drug regulator FDA approves expanded use of Pfizer’s RSV vaccine

The US Food and Drug Administration has greenlighted Pfizer Inc.’s respiratory syncytial virus vaccine (RSV) Abrysvo for treating lower respiratory tract disease in.

Read More
India’s coronary drug-eluting stent market may grow at a compound annual growth rate of 4% until 2033 on the back of a rise in coronary artery diseases, according to UK-based data analytics and consulting company, GlobalData.
Drugs Medical Pharma

Coronary drug-eluting stent market to grow 4% in India till 2033: Report

India’s coronary drug-eluting stent market may grow at a compound annual growth rate of 4% until 2033 on the back of a rise.

Read More
Eli Lilly will license manufacturing know-how of its rheumatoid arthritis baricitinib drug, branded as Olumiant, to Egypt’s EVA Pharma to expand its access to 49 nations in Africa.
Drugs Health Pharma

Eli Lilly to license rheumatoid drug-making technology to Egypt’s EVA

Eli Lilly will license manufacturing know-how of its rheumatoid arthritis baricitinib drug, branded as Olumiant, to Egypt’s EVA Pharma to expand its access to.

Read More
Molecules and microorganisms in the human body dramatically rise or fall at an average age of 44 and 60 affecting both the heart and immune functions, according to a Stanford Medicine study on the biology of ageing.
Drugs Health Pharma

Body undergoes tectonic molecular shifts at age 44, 60: Stanford Medicine

Molecules and microorganisms in the human body dramatically rise or fall at an average age of 44 and 60 affecting both the heart.

Read More
Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the US-based company.
Drugs Health Pharma

J&J plans to acquire Israel’s V-Wave by paying $600 million upfront

Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the.

Read More